Intravitreal Bevacizumab for Low Vision in Neovascular Age-related Macular Degeneration (AMD)

Sponsor
IRCCS San Raffaele
Study ID
NCT01327222
Phase
PHASE3
Status
Completed

Conditions

  • Age Related Macular Degeneration

Eligibility Criteria

Sex
ALL
Age
55 Years - 90 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

The purpose of this study is to compare the effectiveness of intravitreal bevacizumab injection (IVBI) with respect to simple observation in patients with subfoveal choroidal neovascularisation (CNV) secondary to age-related macular degeneration (AMD) presenting at baseline with best corrected visual acuity (BCVA) less than 20/200.

Key Dates

First listed
Apr 1, 2011
Start date
Feb 28, 2011
Status verified
Jan 2011
Primary completion
Feb 28, 2011
Completion
Feb 28, 2011

Study Design

Enrollment
20 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: bevacizumab
    three-monthly intravitreal bevacizumab, followed by PRN monthly injection on the basis of the detection of any fluid on the optical coherence tomography
  • No Intervention: control
    monthly follow-up

Primary Outcome Measure

change in best-corrected visual acuity [ Time Frame: 6 months ]

Related Studies